| 3.83 -0.08 (-2.05%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.8 | 1-year : | 5.6 |
| Resists | First : | 4.11 | Second : | 4.8 |
| Pivot price | 3.68  |
|||
| Supports | First : | 3.65 | Second : | 3.38 |
| MAs | MA(5) : | 3.74 |
MA(20) : | 3.69 |
| MA(100) : | 5.99 |
MA(250) : | 4.78 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 65.4 |
D(3) : | 53.4 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 9.23 | Low : | 2.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SGHT ] has closed below upper band by 28.6%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.9 - 3.92 | 3.92 - 3.94 |
| Low: | 3.75 - 3.77 | 3.77 - 3.79 |
| Close: | 3.8 - 3.83 | 3.83 - 3.86 |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Wed, 15 Apr 2026
Sight Sciences wins $34M patent ruling against Alcon - MSN
Tue, 14 Apr 2026
KCK LTD. Significantly Reduces Stake in Sight Sciences Inc - GuruFocus
Mon, 13 Apr 2026
SGHT: Momentum builds for interventional glaucoma and dry eye, with innovation and adoption accelerating - TradingView — Track All Markets
Sun, 12 Apr 2026
If You Invested $1,000 in Sight Sciences, Inc. (SGHT) - Stock Titan
Mon, 30 Mar 2026
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th - GlobeNewswire
Mon, 30 Mar 2026
Court keeps $34 million award, 10% royalties in eye-stent patent fight - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 54 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 53.2 (%) |
| Shares Short | 1,100 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | -49.7 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -50.8 % |
| Qtrly Rev. Growth | 6.9 % |
| Gross Profit (p.s.) | 1.23 |
| Sales Per Share | 1.43 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -5.18 |
| PEG Ratio | 0 |
| Price to Book value | 3.19 |
| Price to Sales | 2.67 |
| Price to Cash Flow | -6.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|